Supplementary Table S4 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers
crossref(2023)
摘要
Design and outcome details for each AZD8835 in vivo efficacy study.
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要